key: cord-0811399-1cx11veh
authors: Hu, Xingsheng; Hu, Chunhong; Yang, Yong; Chen, Juan; Zhong, Ping; Wen, Yajing; Chen, Xiangyu
title: Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China
date: 2020-11-02
journal: Ther Adv Respir Dis
DOI: 10.1177/1753466620963035
sha: 43fc8d0f2069a551564bab5ad9cca41cc99f611a
doc_id: 811399
cord_uid: 1cx11veh

AIM: To investigate clinical characteristics and identify risk factors for severity of coronavirus disease 2019 (COVID-19) pneumonia outside of Wuhan, China. MATERIALS AND METHODS: We included 213 patients with confirmed COVID-19 who had been discharged or died by 15 March 2020. We retrospectively collected epidemiological, clinical, laboratory, computed tomography imaging and outcome data. Clinical characteristics were described and relative risk factors were compared. RESULTS: Most clinical characteristics of this study were similar to those from studies in Wuhan, but there were lower mortality rate and milder severity. The median time from onset of symptoms to confirmation and hospitalization was 4 and 5 days, respectively. The median virus clearance and shedding times were 10 and 15 days, respectively. When the severe/critical group was compared with the mild/moderate group, significant risk factors included: older age; dyspnea; hypertension; poor appetite; fatigue; higher white cell count, neutrophil count, prothrombin time, creatine kinase, creatine kinase-MB, D-dimer, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and C-reactive protein; and lower lymphocyte count and albumin (p < 0.05). In the intensive care unit (ICU) group compared with the non-ICU group, risk factors included: older age; chronic obstructive pulmonary disease (COPD); dyspnea; poor appetite; higher white cell count, D-dimer, ALT, AST and LDH; and lower lymphocyte count and albumin (p < 0.05). Independent risk factors associated with the severe/critical group were dyspnea [odds ratio (OR) = 19.48], ALT (OR = 6.02) and albumin (OR = 3.36). Independent risk factors associated with the ICU group were dyspnea (OR = 8.88), COPD (OR = 31.80), D-dimer (OR = 8.37), ALT (OR = 28.76) and LDH (OR = 9.95) (p < 0.05). CONCLUSION: The severity of COVID-19 outside Wuhan, China was milder than that within Wuhan. The clinical infective period was long, and the longest virus shedding time was 35 days. The most important risk factors were dyspnea, COPD, D-dimer, ALT, LDH and albumin. The reviews of this paper are available via the supplemental material section.

In December 2019, a new unknown pneumonia emerged in Wuhan, China, and this disease was subsequently named coronavirus disease 2019 . 1 COVID-19 spread rapidly throughout every province of China. Hunan Province, whose location is closest to Wuhan, became the second most affected area. One month later, COVID-19 broke out in Korea, Japan, Europe and America, and by 17 April 2020, it had spread to >200 countries, causing >2 million infections and nearly 150,000 deaths, and these figures are still soaring.

In the reports that described the clinical characteristics of COVID-19, we found obvious differences between Wuhan and elsewhere, with the former having higher mortality rate, acute respiratory distress syndrome (ARDS) rate and disease severity. [2] [3] [4] Reports about the clinical infective period of COVID-19 were rare, such as time from onset of symptoms to confirmation or hospitali zation, virus clearance and virus shedding. Furthermore, although Guan 5 reported a nationwide study of clinical characteristics of COVID-19, that study classified severity according to community-acquired pneumonia criteria, and it did not investigate risk factors for severity of COVID-19, and final follow-up time was not reached (discharged rate 5%). Other studies outside Wuhan that analyzed risk factors for disease severity were also scarce 4, 6 and, more importantly, cut-off dates for follow-up had still not been reached at publication. 4, 7 In this study, we described the characteristics of COVID-19 outside Wuhan, especially the clinical infective period and the time needed for development of different clinical features. We also identified the risk factors for severity of COVID-19 pneumonia.

Patients came from two medical centers, Changsha Public Health Treatment Center and Xiangtan Central Hospital, which were the main treatment centers for COVID-19 in Hunan Province. Inclusion criteria were: (1) laboratory confirmed inpatients with COVID-19; and (2) available epidemiological, clinical and outcomes data. This study was approved by the Institutional Review Board and Ethics Commission of The Second Xiangya Hospital (2020-017), and written informed consent was waived by the Ethics Commission because it was a retrospective analysis on a newly emerging infectious disease.

We retrospectively collected the patient data from the two medical centers. The first date of patient admission was 24 January 2020 and the last date was 16 February 2020. The first discharge date was 4 February 2020 and the last date (final follow-up) was 15 March 2020. We included basic demographic, epidemiological, clinical, laboratory, imaging, therapy, and outcomes data.

Diagnosis of patients COVID-19 was diagnosed on the basis of "Diagnosis and treatment protocol for novel coronavirus infection-induced pneumonia version 7." 8 Confirmation was based on real-time reverse transcription polymerase chain reaction (RT-PCR), nucleic-acid-positive test of respiratory or blood specimens and high-throughput gene sequencing of highly homologous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in respiratory or blood specimens. RT-PCR assays were performed in accordance with the protocol established by the World Health Organization. 9 Outcomes and definitions The primary outcome was patients diagnosed with severe/critical COVID-19, or admission to the intensive care unit (ICU). The secondary outcome was discharge from hospital or death. The incubation period was defined as from exposure to onset of symptoms. 5 Viral clearance time was defined as negative detection of SARS-CoV-2 by RT-PCR at least twice at intervals of 24 h. Clinical viral shedding time was defined as from onset of symptoms to viral clearance. 2 The severity of COVID-19 was classified according to the "Diagnosis and treatment protocol for novel coronavirus infection-induced pneumonia version 7." 8

Continuous variables were expressed as median (interquartile range) and compared with the Mann-Whitney U test. Categorical variables were expressed as number (%) and compared by χ 2 test or Fisher's exact test. Significant variables from univariate analysis were entered into logistic univariate regression analysis for calculating odds ratios (ORs) and statistical significance. Screened out significant variables were entered into logistic multivariate regression analysis for calculating independent risk factors. The statistical analyses were performed by SPSS 25.0 (IBM), and p < 0.05 was considered to be statistically significant.

journals.sagepub.com/home/tar 3 Table 1 .

In all patients, the most common abnormal laboratory examinations were higher C-reactive protein (56.1%) and D-dimer (31.3%), and lower white cell count (35.0%), monocyte count (24.4%), albumin (24.0%) and neutrophil count (20.2%). Elevation of creatine kinase (CK) (10.1%), alanine aminotransferase (ALT) (15.5%), aspartate aminotransferase (AST) (12.7%) and total bilirubin (20.7%) were also found in some patients. Laboratory findings are shown in Table 1 .

In computed tomography (CT) imaging, the most common presentations were ground-glass opacities (93.6%) and bilateral lung involvement (79.7%), but consolidation was rare (6.4%) ( journals.sagepub.com/home/tar 9

The ICU group compared with non-ICU group had significantly older age (57.5 versus 41.0 years); more chronic obstructive pulmonary disease (COPD) (10.0% versus 1.0%), dyspnea (55.0% versus 16.1%) and poor appetite (31.3% versus 8.8%); higher leukocyte count, D-dimer, ALT, AST, LDH, and CRP; and lower monocyte count and albumin (p < 0.05). Results are presented in Table 1 .

We entered the above significant risk factors into logistic univariate analysis to calculate each OR and statistical significance. Except for clustered exposure history (p = 0.836) and involvement of Table 3 . 

Our study described the epidemiological and clinical characteristics of COVID-19 and identified the risk factors for disease severity. Patients in this study had a low exposure to Huanan Seafood Market (0.7%) compared with patients in Wuhan (49-66%). 10, 11 History of smoking was low, although clustered exposure history, visiting Wuhan, and imported disease all accounted for some cases, which agree with the strong infectious characteristics of COVID-19. 5, 7 Most of the patients' clinical manifestations were similar to those in Wuhan studies: 10,12,13 fever (80-98%), cough (76-82%), shortness of breath (31%), and fatigue (32.1-44%). However, for laboratory examination results, compared with studies from Wuhan, we found a lower rate of leukocytosis (4.22% versus 24-30%), lymphopenia (24.4% versus 35-63%), 2,12 mortality rate (1.4% versus 11-28.3%) 2,10 and ARDS (5.6% versus 17-41.8%). 3,10 These characteristics indicated milder severity of COVID-19 outside of Wuhan. Why should this be? One report 14 showed that, from 22 January to 2 March 2020, the mortality rates in Wuhan declined continuously, while those outside Wuhan remained constant. This was due to lack of medical workers and material resources in the early stage of the epidemic. During the outbreak, a large number of health workers from all over the country were dispatched to Wuhan, and acute care beds, temporary hospitals and medical resources were provided, so the mortality curve in Wuhan declined. Our results were consistent with other studies outside of Wuhan. 4,7 In Chen's study, the discharge rate was 87.2%, mortality rate 0.8%, ARDS rate 3.2%, and ICU admission rate 8.8%. 4 In Yang's study, the discharged rate was 49% and mortality, ARDS, and ICU admission rates were all 0%. 7 The median time from onset of symptoms to confirmation in our study was 4 days, which was shorter than Cao's study in Wuhan (9 days). 15 The median time from onset of symptoms to hospitalization was 5 days, which was shorter than studies in Wuhan (6-7 days). 12, 15 These features indicate that, after the outbreak of COVID-19 in Wuhan, awareness of seeing a doctor had increased and government management had been effective. However, we found that the longest time to confirmation and hospitalization was 18 and 21 days, respectively, and these patients were "superspreaders."

Previous studies reported that time from onset of symptoms to virus clearance was 11 and 14 days. 4, 16 We found that the time from confirmation to virus clearance was 10 days, and 14 days if we added the time from symptom onset to confirmation. All three studies showed that virus clearance time in severe/ critical patients was longer than in non-severe/critical patients. One study reported that virus shedding time in Wuhan was a median 20 days (longest 37 days). 2 In our study, the time was 15 days (longest 35 days), with 18 days in the severe/critical group versus 15 days in the mild/moderate group, which suggested that patients in Wuhan had more serious COVID-19 than those outside Wuhan. We found that virus shedding time was associated with the longest clinical infective period, which might bring trouble to the control of virus transmission.

Some patients with severe COVID-19 may rapidly develop ARDS or require ICU admission, and timely intervention is important. The median time from hospital admission to ARDS and ICU admission was 1 (0-4) and 2 (2-4) days, respectively, compared with the time from hospital admission to ICU admission in Wuhan of 1 (0-3) days. 17 Older age and comorbidities were poor predictors of COVID-19. Older age was proved to be associated not only with severity of COVID-19, 2,16 but also with Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. 18, 19 In previous studies of COVID-19, the median of age in severe/ critical, ICU and non-survivor groups was higher than mild/moderate, non-ICU and survivor groups (53.7 years versus 41.9 years, 66 years versus 51 years and 69 years versus 52 years, all p < 0.001). 2, 6, 17 Besides, in our study, if age was calculated as a categorical variable (>50 years versus <50 years), the age >50 years increased risk of severe/critical admission 2.27 times (p = 0.025) and ICU admission 3.75 times (p = 0.01) (Supplemental Material Table  online ). One of the molecular mechanisms may be that older animals have stronger innate inflammation responses to viral infection than younger animals. 20 Another reason was that older people generally combined more comorbidities, however, the latter were associated with the severity of COVID-19, even death, such as hypertension, cardiac disease, COPD or diabetes. 2, 6, 16, 17 As reported, the total incidence of comorbidities in severe/critical, ICU and non-survivor groups was higher than in their comparative groups [44% (11/ In Zhou's study higher white cell count increased the risk of death by 6.6 times, 2 in Li's study lower lymphocyte count increased risk of severe/critical admission by 12.0 times. 6 A high leukocyte count is related to the cytokine storm induced by virus invasion, and low lymphocyte count is related to coronavirus-mediated, severe immune injury. 22 Low albumin level is also a result of immune consumption, which is an equally important poor prognosis factor. 2, 12 In the present study, all of the factors higher white cell, lower lymphocyte and albumin increased the risk of severe/critical and ICU admission, and albumin was an independent predictor of severe/critical group (adjusted OR = 3.36). The cytokine storm activates the coagulation system, which causes elevation of D-dimer and prolonged PT. High D-dimer might cause small thromboses and ischemia in lung capillaries, which trigger the occurrence of dyspnea/ ARDS or DIC, 23 and it is also associated with ICU admission or death. 2, 12, 17 LDH is a tissue injury indicator that is commonly found in all kinds of tissue, including the lungs, so its elevation indicates a more serious inflammatory response in COVID-19, which is associated with ICU admission or death. 2, 12, 16 CRP, an inflammatory factor, is more common than procalcitonin in COVID-19, and it has similar clinical importance to D-dimer and LDH in severe or critical patients. 3, 4, 16 Although elevation of ALT is not more common than that of D-dimer, LDH and CRP, they are more likely to occur in severe or critical patients, and even patients who die, 2,17,24 it increased risk of death by 2.87 times. 2 In the current study, D-dimer and LDH were independently associated with ICU admission, ALT was independently associated with both severe/critical and ICU admission (adjusted OR = 6.02 and 28.76).

Our study had some limitations. First, we included a small number of cases in the critical group (n = 10) and severe group (n = 28), and we did not carry out a comparison between the critical and severe groups. The number of patients in the ICU group was also limited (n = 20) so more cases and multicenter studies are needed outside of Wuhan. Second, the mortality rate was low in our study, so we could not identify the mortality risk factors. Third, we need to investigate more inflammatory factors such as interleukin-2 and -6.

In conclusion, this study described some different characteristics of COVID-19 patients outside of Wuhan, such as fewer complications, lower mortality rate and milder disease severity. We described some important features of the clinical infective period, which may be useful to hospital and government administration. There were many risk factors associated with the severity of COVID-19, among which the most frequent were dyspnea, higher ALT, D-dimer and LDH, and lower albumin. Other factors, such as older age, comorbidity, higher leukocyte count and CRP and lower lymphocyte count, were also important. COVID-19 is prevalent worldwide, and these characteristics may provide references for clinical judgment and early intervention, and may be beneficial to our overall understanding of COVID-19. 

A novel coronavirus from patients with pneumonia in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical progression of patients with COVID-19 in Shanghai

Clinical characteristics of coronavirus disease 2019 in China

The clinical and chest CT features associated with severe and critical COVID-19 pneumonia

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city

National Health Commission of the People's Republic of China. Diagnosis and treatment protocol for novel coronavirus pneumonia

Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: singlecentered, retrospective, observational study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Wuhan and Hubei COVID-19 mortality analysis reveals the critical role of timely supply of medical resources

Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong

Predictors of mortality in Middle East respiratory syndrome (MERS)

Exacerbated innate host response to SARS-CoV in aged non-human primates

Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic?

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis

The authors declare that there is no conflict of interest.

Natural Science Foundation of Hunan Province, NO. 2019JJ40435.

https://orcid.org/0000-0002-4233-8822

The reviews of this paper are available via the supplemental material section.